The relapse rate after transplantation for acute B-lymphoblastic leukemia cannot be specifically determined and is mostly related to the risk stratification of the disease, the type of transplantation, the pretreatment and the presence of pre-transplant extramedullary involvement. The relapse rate alone may range from 20% to 50%.
1. Some patients experience post-transplantation relapse, mostly within 3 years after transplantation. The risk of relapse is mostly related to factors such as disease risk stratification, status of remission of the disease at the time of transplantation, and type of transplantation, pretreatment, etc. The rate of relapse alone may range from 20% to 50%.
2. If immunotherapy such as interleukin-2 or donor lymphocyte infusion is used after transplantation, it can reduce the microscopic residual disease and lower the recurrence rate.
Hematopoietic stem cell transplantation is a very important clinical treatment, widely used in the treatment of malignant hematologic diseases, with the continuous progress of medical technology, the efficacy and safety is significantly improved compared with the previous.
It is recommended to standardize the treatment under the guidance of the doctor and regular review.